ArticleScientific reports2020
Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- A shared tissue transcriptome signature and pathways in psoriasis and ulcerative colitis.Scientific reports · 2022Pooled it
- Potential mechanism of Lactiflorin in treating ulcerative colitis via modulation of the PI3K/AKT pathway: a study integrating network analysis, bioinformatics analysis, and experimental evidence.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Serum cytokine inflammatory profile in children with ulcerative colitis during 6-month follow-up.Scientific reports · 2025Article
- Toward Precision Medicine: Molecular Biomarkers of Response to Tofacitinib in Inflammatory Bowel Disease.Genes · 2025Review
- Anti-integrin αvβ6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype.Journal of Crohn's & colitis · 2025Article
- An Attomolar-Level Optical Device for Monitoring Receptor-Analyte Interactions Without Functionalization Steps: A Case Study of Cytokine Detection.Sensors (Basel, Switzerland) · 2025Article
- Molecular Activity of Inflammation and Epithelial-Mesenchymal Transition in the Microenvironment of Ulcerative Colitis.Gut and liver · 2024Observational
- Selenium Yeast Alleviates Dextran Sulfate Sodium-Induced Chronic Colitis in Mice by Reducing Proinflammatory Cytokines and Regulating the Gut Microbiota and Their Metabolites.Journal of inflammation research · 2024Article
- A Narrative Review of Cytokine Networks: Pathophysiological and Therapeutic Implications for Inflammatory Bowel Disease Pathogenesis.Biomedicines · 2023Review
- C-reactive protein/albumin ratio and IL-6 are associated with disease activity in patients with ulcerative colitis.Journal of clinical laboratory analysis · 2023Article
- Serum cytokines MCP-1 and GCS-F as potential biomarkers in pediatric inflammatory bowel disease.PloS one · 2023Article
- T cell and bacterial microbiota interaction at intestinal and skin epithelial interfaces.Discovery immunology · 2023Review
- Clinical Significance of Serum Elafin in Children with Inflammatory Bowel Disease.Biomedicines · 2022Article
- Association Between Ex Vivo Human Ulcerative Colitis Explant Protein Secretion Profiles and Disease Behaviour.Digestive diseases and sciences · 2022Article
- Lactococcus lactis engineered to deliver hCAP18 cDNA alleviates DNBS-induced colitis in C57BL/6 mice by promoting IL17A and IL10 cytokine expression.Scientific reports · 2022Article
- Article
- Cathelicidin - A Novel Potential Marker of Pediatric Inflammatory Bowel Disease.Journal of inflammation research · 2021Article
- Opportunities to Target T Cell Trafficking in Pediatric Inflammatory Bowel Disease.Frontiers in pediatrics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin 17A (IL-17A) and interleukin 17F (IL-17F) appear to play important role in pathogenesis of some autoimmune diseases. However, their role in inflammatory bowel disease (IBD) has not been yet fully elucidated. We aimed to determine serum IL-17A and IL-17F in children with IBD and to assess their association with IBD activity. Recruited children underwent blood tests including complete blood count, C-reactive protein, erythrocyte sedimentation rate, IL-17A and IL-17F and stool sampling for calprotectin. The study group comprised 68 children with IBD, including 43 with ulcerative colitis and 25 with Crohn's disease. Control group included 20 healthy children. IL-17A was significantly increased in children with IBD (median: 10.95 pg/ml; range: 0.65-200.54 pg/ml) compared to controls (median: 4.09 pg/ml; range: 0.67-26.20 pg/ml) (p = 0.002). IL-17A was significantly increased in patients with active phase of ulcerative colitis (median: 14.58 pg/ml; range: 0.65-200.54 pg/ml) compared to those in ulcerative colitis remission (median: 8.13 pg/ml; range: 1.61-58.56 pg/ml) (p = 0.04). There were no significant differences in IL-17A among patients with active and inactive Crohn's disease (p = 0.18). IL-17F did not differ significantly between children with IBD (median: 15.11 pg/ml; range: 0.09-189.84 pg/ml) and controls (median: 11.56 pg/ml; range: 0.19-32.49 pg/ml) (p = 0.33). Our study suggests that interleukin 17A may diverse active phase from remission only in ulcerative colitis but not in Crohn's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.